- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02102789
A Study of Systemic Chemotherapy With/Without HAI in Patients With Initially Unresectable Colorectal Liver Metastasis
Systemic Chemotherapy With or Without Hepatic Arterial Infusion With Floxuridine in Patients With Initially Unresectable Colorectal Liver Metastasis: A Prospective, Randomised, Controlled Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Yu-hong Li, MD, Ph D
- Email: liyh@sysucc.org.cn
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Recruiting
- Sun Yat-Sen University Cancer Center
-
Contact:
- Yu-hong Li, MD, Ph D
- Email: liyh@sysucc.org.cn
-
Principal Investigator:
- Yu-hong Li, MD, Ph D
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age: 18-70 years old
- Histologically confirmed colorectal adenocarcinoma
- Radiologically or pathologically confirmed diagnosis of colorectal liver metastasis
- Initially unresectable colorectal liver metastasis confirmed by the multidisciplinary team (MDT)
- With no prior treatment for liver metastasis, including chemotherapy, operation, radiotherapy, transcatheter hepatic arterial chemoembolization (TACE) and targeted therapy
- Without extra-hepatic metastasis confirmed by CT, MRI or PET/CT (if necessary) scanning
- With adequate bone marrow function: platelets ≥ 90 x 109/L; white blood cells ≥ 3×109/L; absolute neutrophil count (ANC) ≥ 1.5 x 109/L
- Serum bilirubin ≤ 1.5 x ULN, AST and ALT ≤ 5 x ULN
- Patient has no ascites and with adequate blood coagulation function, albumin ≥ 35 g/L
- Grade A level of Child-Push Liver Function
- Creatinine ≤ 1× ULN, or Calculated Creatinine Clearance >50ml/min (Cockcroft-Gault Equation)
- ECOG performance status of 0-2
- Life expectancy ≥ 3 months
- Not appropriate for anti-EGFR or any other targeted therapy (with KRAS mutation or could not afford it)
- Patients have provided a signed Informed Consent Form
- With good compliance
Exclusion Criteria:
- With any extra-hepatic metastasis and/or primary tumor recurrence
- Severe arterial embolism or ascites
- With hemorrhagic tendency or coagulation disorders
- Hypertensive crisis or hypertensive encephalopathy
- Severe and uncontrolled systemic complications such as infections or diabetes
- Serious cardiovascular diseases such as cerebrovascular accident (within 6 months before enrollment), myocardial infarction (within 6 months before enrollment), uncontrolled hypertension even with appropriate drug intervention, unstable angina pectoris, congestive heart failure (NYHA 2-4 degree), arrhythmia that needs medication intervention
- Patient who has suffered from central nervous system diseases such as primary brain tumor, uncontrolled epilepsy even with standard treatment, any brain metastasis or stroke
- Patient who has a concurrent malignancy or has a malignancy within 5 years before study enrollment, (with the exception of radically resected skin basal cell carcinoma or cervical carcinoma in situ)
- Patient who has received any investigational antineoplastic agent within 28 days before the enrollment
- Any residual toxicity from prior chemotherapy (with the exception of alopecia), such as grade 2 or more sensory peripheral neuropathy (NCI CTC v3.0), oxaliplatin-based regimen will not be considered
- Patient who is allergic to oxaliplatin, leucovorin, 5-Fluorouracil, floxuridine or dexamethasone
- Pregnant or lactating women
- Patient who does not use or refuses to take any appropriate contraceptive measures (intrauterine contraceptive ring, barrier contraception combined with spermicidal gel or sterilization operation), including women of childbearing age (within 2 years after the last menstrual period) and men who are with possible fertility
- Unable or unwilling to comply with the research plan
- The existence of any other disease, dysfunction caused by metastatic lesions, or suspicious disease found on the regular examination, which indicating contraindications to the use of study drugs or may bring high risks of treatment related complications
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Systemic chemotherapy
Patients will receive mFOLFOX6 every 28 days: Oxaliplatin 85 mg/m2 IV over 3 hours on Day 1, 15; Leucovorin (l-LV) 200mg/m2 IV over 2 hours on Day 1, 15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1, 15.
|
Patients will receive mFOLFOX6 every 28 days: Oxaliplatin 85 mg/m2 IV over 3 hours on Day 1, 15; Leucovorin (l-LV) 200mg/m2 IV over 2 hours on Day 1, 15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1, 15.
Other Names:
|
Experimental: Systemic chemotherapy combined with HAI
Patients will receive mFOLFOX6+HAI every 28 days: Oxaliplatin 85 mg/m2 IV over 3 hours on Day 1, 15; Leucovorin (l-LV) 200mg/m2 IV over 2 hours on Day 1, 15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1, 15. 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump. This will be repeated on Day 1 of each 28-day cycle. FUDR will be administered through a 14-day continuous infusion with the HAI pump. |
Patients will receive mFOLFOX6 every 28 days: Oxaliplatin 85 mg/m2 IV over 3 hours on Day 1, 15; Leucovorin (l-LV) 200mg/m2 IV over 2 hours on Day 1, 15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1, 15.
Other Names:
Patients will receive HAI every 28 days: 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump. This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Complete resection rates (R0 resection rates) (defined as no macroscopic or microscopic residual tumor) of both arms
Time Frame: Up to 2-4 months
|
Up to 2-4 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rates (ORR) of both arms
Time Frame: Up to 4-8 monthes
|
Up to 4-8 monthes
|
|
R1 resection rates (with microscopic residual tumor) of both arms
Time Frame: Up to 2-4 monthes
|
Up to 2-4 monthes
|
|
Specific R0/R1 resection plus radiofrequency ablation rates of both arms
Time Frame: Up to 2-4 monthes
|
Up to 2-4 monthes
|
|
Recurrence-free survival (RFS) of both arms
Time Frame: Up to 5 years
|
Time to recurrence or death
|
Up to 5 years
|
5 year cancer specific survival rate of the whole population
Time Frame: Up to 5 years
|
Up to 5 years
|
|
Progression free survival(PFS) of both arms
Time Frame: From the date of first drug administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 monthes
|
From the date of first drug administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 monthes
|
|
Overall survival (OS) of both arms
Time Frame: From the date of first drug administration until the date of death, assessed up to 5 years
|
From the date of first drug administration until the date of death, assessed up to 5 years
|
|
Number of participants with surgical complications, AES and SAEs as a measure of safety
Time Frame: Each follow up visit, assessed up to 2 years
|
Each follow up visit, assessed up to 2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yu-hong Li, MD, Ph D, Sun Yat-sen University
Study record dates
Study Major Dates
Study Start
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Protective Agents
- Micronutrients
- Vitamins
- Antidotes
- Vitamin B Complex
- Dexamethasone
- Fluorouracil
- Oxaliplatin
- Leucovorin
- Floxuridine
Other Study ID Numbers
- Frozen-2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Colorectal Cancer
-
Mayo ClinicCompletedMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic... and other conditionsUnited States
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...Active, not recruitingColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
-
Array Biopharma, now a wholly owned subsidiary...CompletedMetastatic Colorectal Cancer | Advanced Solid Tumors | Advanced or Metastatic Biliary CancerUnited States
-
Hutchison Medipharma LimitedActive, not recruitingMetastatic Colorectal Cancer | Metastatic Colon CancerUnited States, Spain, Japan, Australia, Austria, Belgium, Czechia, Estonia, France, Germany, Hungary, Italy, Poland, United Kingdom
-
Zhejiang Cancer HospitalNot yet recruitingMetastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRCChina
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Malignant... and other conditionsUnited States
-
Dana-Farber Cancer InstituteAmerican Cancer Society, Inc.Not yet recruitingMetastatic Colorectal Cancer | Colorectal Cancer | Metastatic Colon CancerUnited States
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer | Oncology
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer
-
Rottapharm BiotechAgenus Inc.Active, not recruitingSolid Tumor | Metastatic Microsatellite-stable Colorectal Cancer | Mismatch Repair Protein Proficient | Refractory Metastatic Colorectal CancerItaly
Clinical Trials on mFOLFOX6
-
Fudan UniversityRecruitingColorectal CancerChina
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityRecruitingColorectal Cancer | Adjuvant ChemotherapyChina
-
Rui-hua Xu, MD, PhDNot yet recruitingAdvanced Pancreatic CancerChina
-
Xu jianminUnknownNeoplasm Metastasis | Liver Neoplasms | Colorectal NeoplasmsChina
-
Shanghai Henlius BiotechNot yet recruiting
-
Fujian Cancer HospitalNot yet recruitingAdvanced Colorectal Cancer
-
NRG OncologyNational Cancer Institute (NCI); Natera, Inc.RecruitingStage III Colon CancerUnited States, Canada
-
Martin-Luther-Universität Halle-WittenbergGALMED GmbHCompleted
-
Fujian Medical University Union HospitalRecruitingRectal Cancer | Radiation OncologyChina
-
Centre Hospitalier Universitaire DijonRecruitingPatients With Resected Stage II Colon CancerFrance